Tech Company Financing Transactions
Zentalis Pharmaceuticals Funding Round
Zentalis Pharmaceuticals secured a $85 million Series C financing round on 12/11/2019. Investors included Eventide Asset Management, Farallon Capital Management and Matrix Capital Management.
Transaction Overview
Company Name
Announced On
12/11/2019
Transaction Type
Venture Equity
Amount
$85,000,000
Round
Series C
Investors
Proceeds Purpose
The proceeds from the Series C financing will be used to advance the Company's lead clinical candidates towards pivotal trials and to broaden the scope of Zentalis' ongoing clinical programs.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
530 Seventh Ave. 2201
New York, NY 10018
USA
New York, NY 10018
USA
Phone
Website
Email Address
Overview
At Zentalis (Nasdaq: ZNTL), we are developing clinically differentiated therapeutics targeting fundamental cancer pathways that have the potential to address major unmet medical needs for patients with cancer. We have successfully advanced three compounds into the clinic in the Company's first five years, all internally developed using the deep chemistry capabilities of our integrated discovery engine.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 12/11/2019: HypeLabs venture capital transaction
Next: 12/11/2019: Imply venture capital transaction
Share this article
News on VC Transactions
We report on every notable VC transaction. All VC database entries on this site are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs